Laboratory of Medical Genetics, Translational Cytogenomics Research Unit, Bambino Gesù Children Hospital, IRCCS, Rome, Italy.
Medical Genetics Unit, Bambino Gesù Children Hospital, IRCCS, Rome, Italy.
Eur J Hum Genet. 2022 Nov;30(11):1239-1243. doi: 10.1038/s41431-022-01153-3. Epub 2022 Jul 26.
Neurofibromatosis type 1 (NF1), an autosomal dominant disorder characterized by skin pigmentary lesions and multiple cutaneous neurofibromas, is caused by neurofibromin 1 (NF1) loss of function variants. Currently, a molecular diagnosis is frequently established using a multistep protocol based on cDNA and gDNA sequence analysis and/or Multiplex Ligation-dependent Probe Amplification (MLPA) assay on genomic DNA, providing an overall detection rate of about 95-97%. The small proportion of clinically diagnosed patients, which at present do not obtain a molecular confirmation likely are mosaic, as their pathogenic variant may remain undetected due to low sensitivity of low coverage NGS approaches, or they may carry a type of pathogenic variant refractory to currently used technologies. Here, we report two unrelated patients presenting with two different inversions that disrupt the NF1 coding sequence, resulting in an NF1 phenotype. In one subject, the inversion was associated with microdeletions spanning a few NF1 exons at both breakpoints, while in the other the rearrangement did not cause exon loss, thus testing negative by MLPA assay. Considering the high proportion of repeated regions within the NF1 sequence, we propose that intragenic structural rearrangements should be considered as possible pathogenic mechanisms in patients fulfilling the NIH diagnostic criteria of NF1 but lacking of molecular confirmation and in patients with NF1 intragenic microdeletions.
神经纤维瘤病 1 型(NF1)是一种常染色体显性遗传病,其特征为皮肤色素沉着病变和多发性皮肤神经纤维瘤,由神经纤维瘤蛋白 1(NF1)功能丧失变异引起。目前,常采用基于 cDNA 和 gDNA 序列分析和/或基因组 DNA 的多重连接依赖性探针扩增(MLPA)检测的多步骤方案进行分子诊断,总体检测率约为 95-97%。目前,临床上诊断的一小部分患者未获得分子确认,可能是嵌合体,因为由于低覆盖度 NGS 方法的灵敏度较低,其致病性变异可能未被检测到,或者他们可能携带对当前使用的技术有抗性的致病性变异。在这里,我们报告了两例不相关的患者,他们表现出两种不同的倒位,破坏了 NF1 编码序列,导致 NF1 表型。在一个患者中,倒位与两个断点处跨越几个 NF1 外显子的微缺失有关,而在另一个患者中,重排未导致外显子缺失,因此 MLPA 检测呈阴性。鉴于 NF1 序列中重复区域的比例很高,我们提出在符合 NIH NF1 诊断标准但缺乏分子确认的患者和具有 NF1 基因内微缺失的患者中,应考虑基因内结构重排作为可能的致病机制。